Safety and value driving Phase IV growth at CROs; EVP

By Gareth Macdonald

- Last updated on GMT

Related tags: Vice president, Contract research organization

Safety and value driving Phase IV growth at CROs; EVP
Increased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.

Jeff Trotter, executive vice president of Phase IV development at PharmaNet, told Outsourcing-Pharma that “the real world is real important​”. In recent years post-market safety has become increasingly important, boosting Phase IV business for contract research organisations (CRO).

This is now being accompanied by increased focus on value. Trotter said this spans other indications, cost-effectiveness and comparative effectives. More and more regulators will request post-approval data to prove a product has lived up to promise, said Trotter.

In April PharmaNet made three executive appointments to its Phase IV team.

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars